阿里莫克洛莫尔:第一次批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
阿里莫克洛莫尔现在已在美国获得批准,用于治疗2岁及以上患者的神经学尼曼-皮克病C型 (NPC). 这种口服药物通过改善 lysosomal 功能而起作用,并与 miglustat.一起使用.
科学领域:
- 神经学 神经学
- 溶酶体储存疾病 溶酶体储存疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 尼曼-皮克病C型 (NPC) 是一种罕见的遗传疾病,影响 lysosomal 功能并引起神经症状.
- 阿里莫克洛莫尔 (MIPLYFFATM) 是一种口服小分子药物,旨在增强溶解体功能.
- 众所周知,该药物可以穿越血脑屏障,并调节CLEAR网络基因.
研究的目的:
- 总结一下阿里莫克洛莫尔的发展里程碑.
- 要强调最近美国FDA批准治疗NPC的神经表现.
- 详细说明其在成人和儿科患者中与miglustat结合使用.
主要方法:
- 审查阿里莫克洛莫尔的发展途径.
- 支持其在NPC中的疗效和安全性的临床数据摘要.
- 监管里程碑的文件,导致批准.
主要成果:
- 阿里莫克洛莫尔在改善与NPC相关的溶酶体功能方面显示出潜在的潜力.
- 该药物于2024年9月在美国获得批准,用于与miglustat.
- 批准涵盖2岁及以上的神经NPC的成人和儿科患者.
结论:
- 阿里莫克洛莫尔代表了对尼曼 - 皮克病C型的显著治疗进展.
- 组合疗法为减弱神经症状提供了一种新的治疗选择.
- 此次批准标志着罕见病药物开发的重大里程碑.
更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Regulation
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
